BIO-TECHNE Corp Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
BIO-TECHNE Corp (TECH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $19.16 per share for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-24
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $18.86, a 25.51% decline year-over-year.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-09-30 was $25.32, a 11.41% decline year-over-year.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-09-30 was $28.58, a 3.61% decline year-over-year.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-09-30 was $29.65, a 74.97% decline year-over-year.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2026 was $19.16, a 22.59% decline from fiscal 2025.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $24.75, a 9.24% decline from fiscal 2024.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $27.27, a 7.65% decline from fiscal 2023.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $29.53, a 0.84% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $19.16 10-K · filed 2026-08-24 | |||||||
| 2026-03-31 | $19.15 10-Q · filed 2026-05-06 | |||||||
| 2025-12-31 | $19.13 10-Q · filed 2026-02-04 | |||||||
| 2025-09-30 | $18.86 10-Q · filed 2025-11-05 | |||||||
| 2025-06-30 | $24.75 10-K · filed 2026-08-24 | |||||||
| 2025-03-31 | $25.44 10-Q · filed 2026-05-06 | |||||||
| 2024-12-31 | $25.43 10-Q · filed 2026-02-04 | |||||||
| 2024-09-30 | $25.32 10-Q · filed 2025-11-05 | |||||||
| 2024-06-30 | $27.27 10-K · filed 2026-08-24 | |||||||
| 2024-03-31 | $27.47 10-Q · filed 2025-05-08 | |||||||
| 2023-12-31 | $27.83 10-Q · filed 2025-02-06 | |||||||
| 2023-09-30 | $28.58 10-Q · filed 2024-11-05 | |||||||
| 2023-06-30 | $29.53 10-K · filed 2025-08-22 | |||||||
| 2023-03-31 | $29.58 10-Q · filed 2024-05-06 | |||||||
| 2022-12-31 | $29.62 10-Q · filed 2024-02-07 | |||||||
| 2022-09-30 | $29.65 10-Q · filed 2023-11-07 | $118.60 10-Q · filed 2022-11-07 | ||||||
| 2022-06-30 | $29.78 10-K · filed 2024-08-22 | $119.11 10-K · filed 2022-08-24 | ||||||
| 2022-03-31 | $29.77 10-Q · filed 2023-05-08 | $119.10 10-Q · filed 2022-05-09 | ||||||
| 2021-12-31 | $29.82 10-Q · filed 2023-02-07 | $119.27 10-Q · filed 2022-02-07 | ||||||
| 2021-09-30 | $118.47 10-Q · filed 2022-11-07 | |||||||
| 2021-06-30 | $14.94 10-K · filed 2023-08-23 | $59.75 10-K · filed 2021-08-25 | ||||||
| 2021-03-31 | $57.50 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | $56.88 10-Q · filed 2022-02-07 | |||||||
| 2020-09-30 | $56.71 10-Q · filed 2021-11-08 | |||||||
| 2020-06-30 | $37.01 10-K · filed 2022-08-24 | |||||||
| 2020-03-31 | $37.01 10-Q · filed 2021-05-07 | |||||||
| 2019-12-31 | $37.00 10-Q · filed 2021-02-08 | |||||||
| 2019-09-30 | $36.72 10-Q · filed 2020-11-09 | |||||||
| 2019-06-30 | $34.66 10-K · filed 2021-08-25 | |||||||
| 2019-03-31 | $34.66 10-Q · filed 2020-05-11 | |||||||
| 2018-12-31 | $34.69 10-Q · filed 2020-02-06 | |||||||
| 2018-09-30 | $34.30 10-Q · filed 2019-11-06 | |||||||
| 2018-06-30 | $22.07 10-K · filed 2020-08-26 | |||||||
| 2018-03-31 | $21.98 10-Q · filed 2019-05-07 | |||||||
| 2017-12-31 | $21.58 10-Q · filed 2019-02-07 | |||||||
| 2017-09-30 | $20.47 10-Q · filed 2018-11-07 | |||||||
| 2017-06-30 | $18.21 10-K/A · filed 2019-11-06 | |||||||
| 2017-03-31 | $18.13 10-Q · filed 2018-05-09 | |||||||
| 2016-12-31 | $18.13 10-Q · filed 2018-02-08 | |||||||
| 2016-09-30 | $17.98 10-Q · filed 2017-11-09 | |||||||
| 2016-06-30 | $18.50 10-K · filed 2018-08-27 | |||||||
| 2016-03-31 | $18.50 10-Q · filed 2017-05-10 | |||||||
| 2015-12-31 | $18.59 10-Q · filed 2017-02-09 | |||||||
| 2015-09-30 | $18.48 10-Q · filed 2016-11-09 | |||||||
| 2015-06-30 | $15.01 10-K · filed 2017-09-07 | |||||||
| 2015-03-31 | $15.08 10-Q · filed 2016-05-10 | |||||||
| 2014-12-31 | $14.27 10-Q · filed 2016-02-09 | |||||||
| 2014-09-30 | $13.93 10-Q · filed 2015-11-09 | |||||||
| 2014-06-30 | $14.77 10-K · filed 2016-08-29 | |||||||
| 2014-03-31 | $14.97 10-Q · filed 2015-05-11 | |||||||
| 2013-12-31 | $14.97 10-Q · filed 2015-02-09 | |||||||
| 2013-09-30 | $13.94 10-Q · filed 2014-11-10 | |||||||
| 2013-06-30 | $9.72 10-K · filed 2015-08-31 | |||||||
| 2012-09-30 | $11.85 10-Q · filed 2012-11-09 | |||||||
| 2012-06-30 | $14.14 10-K · filed 2014-08-29 | |||||||
| 2012-03-31 | $12.48 10-Q · filed 2012-05-10 | $14.14 10-Q · filed 2012-05-10 | ||||||
| 2011-12-31 | $15.68 10-Q · filed 2012-02-07 | $14.90 10-Q · filed 2012-02-07 | ||||||
| 2011-09-30 | $13.66 10-Q · filed 2012-11-09 | |||||||
| 2011-06-30 | $14.58 10-K · filed 2013-08-29 | |||||||
| 2011-03-31 | $15.02 10-Q · filed 2012-05-10 | |||||||
| 2010-12-31 | $15.70 10-Q · filed 2012-02-07 | $15.02 10-Q · filed 2012-02-07 | ||||||
| 2010-09-30 | $9.67 10-Q · filed 2011-11-09 | |||||||
| 2010-06-30 | $14.76 10-K · filed 2012-08-29 | |||||||
| 2009-06-30 | $28.21 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |